​

Cadrenal Therapeutics Stock (NASDAQ:CVKD)

RevenueFinancialsChart
Cadrenal Therapeutics by TradingView

Previous Close

$12.04

52W Range

$8.74 - $22.90

50D Avg

$13.43

200D Avg

$14.86

Market Cap

$26.10M

Avg Vol (3M)

$27.43K

Beta

0.98

Div Yield

-

CVKD Company Profile

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

4

IPO Date

Jan 20, 2023

Website

CVKD Performance

CVKD Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-10.96M$-7.63M$-2.70M
Net Income-$-8.36M$-6.71M
EBITDA$-10.96M$-8.34M$-6.61M
Basic EPS$-8.73$-9.63$-8.66
Diluted EPS$-8.73$-9.63$-8.66

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
XCURExicure, Inc.
IBIOiBio, Inc.
TAOXTAO Synergies Inc.
RLYBRallybio Corporation
KLTOKlotho Neurosciences, Inc.
CLGNCollPlant Biotechnologies Ltd.
NRSNNeuroSense Therapeutics Ltd.
SONNSonnet BioTherapeutics Holdings, Inc.
ITRMIterum Therapeutics plc